December 3, 2018 08:39 AM EST
Pharma

Fi­nal­ly sat­is­fied with Oc­u­lar's man­u­fac­tur­ing set­up, FDA ap­proves eye drug/de­vice Dex­ten­za

ENDPOINTS

Af­ter two FDA re­jec­tions that cul­mi­nat­ed in a man­age­ment shake-up and staff cuts, Oc­u­lar Ther­a­peu­tix’s $OCUL eye drug/de­vice Dex­ten­za has fi­nal­ly got the

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times